Synthesis and optimization of the labeling procedure of 99mTc-Hynic-Interleukin-2 for in vivo imaging of activated T lymphocytes

Molecular Imaging and Biology

Volumn 12, Issue 5, 2010, Pages 539-546

  D'Alessandria, Calogero ^a   Di Gialleonardo, Valentina ^a,b   Chianelli, Marco ^b,c   Mather, Stephen J ^d   De Vries, Erik F J ^b   Scopinaro, Francesco ^a   Dierck, Rudi A ^b   Signore, Alberto ^a,b,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Inflammation; Interleukin 2; Molecular imaging; Radiopharmacy

Indexed keywords

CHELATING AGENT; ORGANIC COMPOUND; RECOMBINANT INTERLEUKIN 2; SUCCINIMIDYL 6 HYDRAZINOPYRIDINE 3 CARBOXILATE; TECHNETIUM 99M; TRICINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CELL AGGREGATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LYMPHOCYTE MIGRATION; MOLECULAR IMAGING; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELIABILITY; REPRODUCIBILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STANDARDIZATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CHROMATOGRAPHY, LIQUID; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; ORGANOTECHNETIUM COMPOUNDS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

MUS;

EID: 78049325522     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0285-1     Document Type: Article

References (10)

1. F Foss 2006 Clinical experience with denileukin diftitox (ONTAK) Semin Oncol 33 1 Suppl 3 S21 S25 1:CAS:528:DC%2BD28XjtlGrsr0%3D 10.1053/j.seminoncol. 2005.12.019 16516672
2. A Signore M Chianelli A Annovazzi, et al. 2000 Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet Eur J Nucl Med 27 1 18 24 1:CAS:528:DyaK1MXnvFektr0%3D 10.1007/PL00006657 10654142
3. A Annovazzi L Biancone R Caviglia, et al. 2003 99mTc-interleukin-2 and 99mTc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease Eur J Nucl Med 30 374 382 1:CAS:528:DC%2BD3sXitFGmtb8%3D 10.1007/s00259-002- 1069-x
4. A Signore A Picarelli M Chianelli, et al. 1996 123I-Interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity J Pedriatr Endocrinol Metab 9 139 144
5. A Signore A Annovazzi R Barone, et al. 2004 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study J Nucl Med 45 10 1647 1652 15471828
6. D Loose A Signore L Staelens, et al. 2008 (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma Eur J Nucl Med Mol Imaging 35 2 281 286 1:CAS:528:DC%2BD1cXosVegsQ%3D%3D 10.1007/s00259-007-0609-9 17929011
7. M Chianelli A Signore AR Fritzberg SJ Mather 1997 The development of Technetium-99 m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases Nucl Med Biol 24 579 586 1:CAS:528:DyaK2sXmt1ajsL4%3D 10.1016/S0969-8051(97)00021-8 9316088 (Pubitemid 27405027)
8. MJ Abrams M Juweid CI tenKate, et al. 1990 Technetium-99 m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats J Nucl Med 31 12 2022 2028 1:CAS:528:DyaK3MXhvVWns70%3D 2266401
9. KA Smith 1988 Interleukin-2: inception, impact and implications Science 240 1169 1176 1:CAS:528:DyaL1cXkt1Whtrs%3D 10.1126/science.3131876 3131876
10. M Chianelli MG Parisella C D'Alessandria F Corsetti F Scopinaro A Signore 2003 The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options Q J Nucl Med 47 256 269 1:STN:280:DC%2BD2c%2Fotl2ltA%3D%3D 14973418